Procedures

WWARN is continually updating a library of standardised procedures that offer guidance in the execution of various activities in the fields of clinical, in vitro, pharmacology, data collection and molecular analysis for antimalarial drug resistance researchers. Please read our tools and resources usage guidance.

For resources that relate to other infectious and emerging diseases, visit iddo.org.

Publication Code: MOL01

Collecting and preserving DNA, RNA and parasite isolates from infected blood samples

Version: v1.5

Publication Code: IP05

Ensuring integrity of the trial through a randomisation and blinding process

Version: 2.0

Publication Code: CL22

These guidelines aim to standardize the sample collection procedure during clinical studies of artemisinin antimalarial drugs

Version: 2.0

Publication Code: CL19

These guidelines aim to standardize the sample collection procedure during clinical studies of lumefantrine / desbutyl-lumefantrine antimalarial drugs

Version: 2.0

Publication Code: IP04

Returning investigational products/study drugs to the sponsor or arranging for their destruction at the trial site

Version: 2.0

Publication Code: CL21

These guidelines aim to standardize the sample collection procedure during clinical studies of primaquine / carboxyprimaquine antimalarial drugs

Version: 2.0

Publication Code: CL19

These guidelines aim to standardize the sample collection procedure during clinical studies of lumefantrine / desbutyl-lumefantrine antimalarial drugs

Version: 2.0

Publication Code: IP03

Dispensing and dosing of investigational products/study drugs and their return to a pharmacy/drug store for a clinical trial.

Version: 2.0

Publication Code: CL18

These guidelines aim to standardize the sample collection procedure during clinical studies of amodiaquine / desethylamodiaquine antimalarial drugs

Version: 2.0

Publication Code: QA09

A process for how training of trial staff will be planned and documented

Version: 2.0